BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38394770)

  • 1. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
    Shah NP; Bhatia R; Altman JK; Amaya M; Begna KH; Berman E; Chan O; Clements J; Collins RH; Curtin PT; DeAngelo DJ; Drazer M; Maness L; Metheny L; Mohan S; Moore JO; Oehler V; Pratz K; Pusic I; Rose MG; Shomali W; Smith BD; Styler M; Talpaz M; Tanaka TN; Tantravahi S; Thompson J; Tsai S; Vaughn J; Welborn J; Yang DT; Sundar H; Gregory K
    J Natl Compr Canc Netw; 2024 Feb; 22(1):43-69. PubMed ID: 38394770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
    Deininger MW; Shah NP; Altman JK; Berman E; Bhatia R; Bhatnagar B; DeAngelo DJ; Gotlib J; Hobbs G; Maness L; Mead M; Metheny L; Mohan S; Moore JO; Naqvi K; Oehler V; Pallera AM; Patnaik M; Pratz K; Pusic I; Rose MG; Smith BD; Snyder DS; Sweet KL; Talpaz M; Thompson J; Yang DT; Gregory KM; Sundar H
    J Natl Compr Canc Netw; 2020 Oct; 18(10):1385-1415. PubMed ID: 33022644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology.
    Radich JP; Deininger M; Abboud CN; Altman JK; Berman E; Bhatia R; Bhatnagar B; Curtin P; DeAngelo DJ; Gotlib J; Hobbs G; Jagasia M; Kantarjian HM; Maness L; Metheny L; Moore JO; Pallera A; Pancari P; Patnaik M; Purev E; Rose MG; Shah NP; Smith BD; Snyder DS; Sweet KL; Talpaz M; Thompson J; Yang DT; Gregory KM; Sundar H
    J Natl Compr Canc Netw; 2018 Sep; 16(9):1108-1135. PubMed ID: 30181422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic Myeloid Leukemia with cryptic Philadelphia translocation and extramedullary B-lymphoid blast phase as an initial presentation.
    Soliman DS; Amer AM; Mudawi D; Al-Sabbagh Z; Alkuwari E; Al-Sabbagh A; Ibrahim F; Yassin MA
    Acta Biomed; 2018 Apr; 89(3-S):38-44. PubMed ID: 29633732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Research advance on molecular genetics of CML blast crisis].
    Zhu HQ; Zhang S; Liu XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias.
    Maiti A; Franquiz MJ; Ravandi F; Cortes JE; Jabbour EJ; Sasaki K; Marx K; Daver NG; Kadia TM; Konopleva MY; Masarova L; Borthakur G; DiNardo CD; Naqvi K; Pierce S; Kantarjian HM; Short NJ
    Acta Haematol; 2020; 143(6):567-573. PubMed ID: 32289808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Update on the Management of Advanced Phase Chronic Myeloid Leukemia.
    Short NJ; Senapati J; Jabbour E
    Curr Hematol Malig Rep; 2023 Dec; 18(6):234-242. PubMed ID: 37651057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2022 Sep; 97(9):1236-1256. PubMed ID: 35751859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blast phase of chronic myeloid leukemia with concurrent BCR::ABL1 and SET::NUP214: A report of two cases.
    Chen Y; Wang Q; Cen J; Xu C; Tao TT; Xie J; Shen W; Gong Y; Pan J; Yao L
    Mol Carcinog; 2023 Feb; 62(2):117-121. PubMed ID: 36321418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
    Chen Z; Shao C; Wang W; Zuo Z; Mou X; Hu SJ; DiGiuseppe JA; Zu Y; Medeiros LJ; Hu S
    Leukemia; 2017 Mar; 31(3):585-592. PubMed ID: 27560111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A rare BCR-ABL1 transcript in chronic myeloid leukemia: Case report and literature review.
    Zhao ZY; Tang N; Lin LE
    Leuk Res; 2023 Oct; 133():107369. PubMed ID: 37660636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2020 Jun; 95(6):691-709. PubMed ID: 32239758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does eventually NPM1 mutation in blast phase chronic myeloid leukemia (BP-CML) exist? That is the question.
    Henry A; Bracquemart C; Naguib D; Chantepie S; Cheze S; Johnson-Ansah HA
    Br J Haematol; 2021 Nov; 195(3):469-471. PubMed ID: 34396510
    [No Abstract]   [Full Text] [Related]  

  • 16. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No correlation between locations of bcr breakpoints and clinical states in Ph1-positive CML patients.
    Ogawa H; Sugiyama H; Soma T; Masaoka T; Kishimoto S
    Leukemia; 1989 Jul; 3(7):492-6. PubMed ID: 2733454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation.
    Boucher L; Rozalska L; Sorel N; Olivier G; Hernanz MPG; Cayssials E; Raimbault A; Chomel JC
    Leuk Res; 2024 Feb; 137():107439. PubMed ID: 38281466
    [No Abstract]   [Full Text] [Related]  

  • 19. Optimal Response in a Patient With CML Expressing
    Manzella L; Tirrò E; Vitale SR; Puma A; Consoli ML; Tambè L; Pennisi MS; DI Gregorio S; Romano C; Tomarchio C; DI Raimondo F; Stagno F
    In Vivo; 2020; 34(3):1481-1486. PubMed ID: 32354950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia.
    Shin JE; Kim SH; Kong M; Kim HR; Yoon S; Kee KM; Kim JA; Kim DH; Park SY; Park JH; Kim H; No KT; Lee HW; Gee HY; Hong S; Guan KL; Roe JS; Lee H; Kim DW; Park HW
    Mol Cancer; 2023 Nov; 22(1):177. PubMed ID: 37932786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.